Evolus (EOLS) Capital Expenditures (2018 - 2026)
Evolus' (EOLS) quarterly Capital Expenditures came in at $12000.0 in Q1 2026, down 96.24% YoY from $319000.0 in Q1 2025, and down 98.25% on a QoQ basis from $687000.0 in Q4 2025.
Evolus (EOLS) Capital Expenditures (2018 - 2026) Analysis & Trends
Evolus (EOLS) has 9 years of Capital Expenditures data on file, last reported at $12000.0 in Q1 2026.
- Quarterly Capital Expenditures fell 96.24% year-over-year to $12000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.7 million (up 206.45% YoY) and the FY2025 annual result came in at $5.0 million, up 240.42% from the prior year.
- Capital Expenditures retreated to $12000.0 in Q1 2026, from $687000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $2.8 million in Q2 2025 to a low of -$296000.0 in Q3 2024.
- A 5-year average of $545117.6 and a median of $346000.0 in 2022 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2022 — Capital Expenditures jumped 13033.33% — and 2024, when it slumped 158.04%.
- Tracing EOLS's Capital Expenditures over 5 years: stood at $866000.0 in 2022, then sank by 82.45% to $152000.0 in 2023, then jumped by 188.16% to $438000.0 in 2024, then surged by 56.85% to $687000.0 in 2025, then tumbled by 98.25% to $12000.0 in 2026.
- The last three Capital Expenditures figures came in at $12000.0 (Q1 2026), $687000.0 (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 104.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 117.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | -337.60 Mn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 108.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 52.80 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 7.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 33.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Evolus | 550.84 Mn | 505.67 Mn | 57.18 Mn | 450,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 450,000.00 |
| Jun 30, 2026 | 450,000.00 |
| Mar 31, 2026 | 12,000.00 |
| Mar 31, 2026 | 12,000.00 |
| Dec 31, 2025 | 687,000.00 |
| Dec 31, 2025 | 687,000.00 |
| Sep 30, 2025 | 1.20 Mn |
| Sep 30, 2025 | 1.20 Mn |
| Jun 30, 2025 | 2.80 Mn |
| Jun 30, 2025 | 2.80 Mn |
| Mar 31, 2025 | 319,000.00 |
| Mar 31, 2025 | 319,000.00 |
| Dec 31, 2024 | 438,000.00 |
| Dec 31, 2024 | 438,000.00 |
| Sep 30, 2024 | -296,000.00 |
| Sep 30, 2024 | -296,000.00 |
| Jun 30, 2024 | 1.07 Mn |
| Jun 30, 2024 | 1.07 Mn |
| Mar 31, 2024 | 256,000.00 |
| Mar 31, 2024 | 256,000.00 |